Respiratory

News on diagnostics for respiratory pathogens, including influenza, coronavirus, and more.

Developers claim the immunochromatographic assay has advantages over other tests on the market for diagnosing TB in HIV patients, as well as the conventional approach.

The three-year extension increases the minimum purchase commitments for the Unyvero system, resulting in an increase in potential revenues of €30 million to Curetis.

Smaller multiplex molecular panels of five or fewer targets will be covered, while a determination of gastrointestinal panel coverage is expected soon.

ProAxsis and a US-based biotechnology company codeveloped the assay as part of an ongoing collaboration. ProAxsis has made its first commercial sale of the test.

In a study of 264 men suspected of having sleep apnea, the three-marker panel outperformed several existing clinical measures for diagnosing the condition.